Impact of Stress on Cardiovascular Events in Patients with Peripheral Arterial Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen

About this trial

Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality worldwide. Patients with peripheral arterial disease are at increased risk suffering from major adverse cardiac and limb events. Acute and chronic stress affect the cardiovascular system. Long-term negative stressors lead to cardiovascular diseases and can aggravate already existing cardiovascular diseases. However, current guidelines on cardiovascular disease prevention highlight stress as a cardiovascular risk factor there is a lack of consensus about the definition and measurement of stress. The aim of the proposed trial is to evaluate different stress measuring methods in patients with PAD depending on the occurrence of cardiovascular events.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Limb bypass surgery or

aorta-femoral bypass surgery or

percutaneous transluminal angioplasty revascularization of the iliac or infrainguinal arteries or

limb or foot amputation for arterial vascular disease or

Disqualifiers

atrial fibrillation

high premature ventricular contractions burden

pacemaker with constant ventricular pacing

antiarrhythmic drugs class I or III

Trial population

The recruitment process and examinations will take place at the Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

300 Participants
are grouped into 1 trial group
Group A: Patients with peripheral arterial disease.

Trial outcomes

Primary outcomes

1

Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), Coronary Heart Disease (CHD) Death, or chronic limb ischemia and amputation

Based on the COMPASS trial MACE and MALE includes the composite of cardiovascular death, myocardial infarction, acute limb ischaemia, chronic limb ischaemia and amputation. MACE and MALE will be evaluated at baseline and after 6 and 12 months

Time frame
Baseline, after 6 months, after 12 months
2

Pychological stress

Pychological stress is evaluated by a composite psychometric measure of stress level by using a mean rank at baseline and after 1 year. It is based on a published RCT by Blumenthal et al. and includes the Beck Depression Inventory II (BDI-II), State-Trait Anxiety inventory (STAI), Patient-Reported Outcomes Measurement Information System (PROMIS) Anger, General Health Questionnaire (GHQ) and Perceived Stress Scale (PSS). A range from 1 to 147 was present with higher scores suggestive of better function

Time frame
Baseline, after 6 months, after 12 months
3

Heart rate variability (HRV)

Heart rate variability (HRV) is an indirect marker of autonomic nervous system activity and describes the oscillations between the R-R intervals in the electrocardiogram. It allows a relatively superficial insight into the heart-brain interaction and reflects the psycho-emotional status such as stress or anxiety. According to the guidelines we chose a short-time HRV with 5 minutes of recording

Time frame
Baseline, after 6 months, after 12 months
4

Proinflammatory mediators - IL-6

IL-6 is measured in pg/ml. Standard value is under 2.7 pg/ml. Higher values indicate an increased stress level

Time frame
Baseline, after 6 months, after 12 months

Secondary outcomes

1

Health-related quality of life

We will apply two instrument to measure health-related quality of life. Namely the Short Form-36 health questionnaire and the European Quality of Life 5 Dimensions 5 Level survey (EQ-5D-5L). The SF-36 is an eight-dimensional scale consisting of 36 items. It assesses health-related quality of life based on physical, social, and psychological functioning, role behavior due to physical and psychological functional impairment, physical pain, general health perception, and vitality. The EQ-5D-5L consists of five health-related dimensions that can be assessed at five levels. In addition, the questionnaire contains a visual analog scale for assessing general health

Time frame
Baseline, after 6 months, after 12 months
2

Ankle-brachial index (ABI)

The lower systolic ankle pressure is set in relation to the systolic blood pressure of the upper extremity. The lowest calculated ABI will be used. Normal values are 0.9 to 1.2. ABI values below 0.9 are indicative of PAD, with an ABI below 0.5 showing severe limb ischaemia

Time frame
Baseline, after 6 months, after 12 months
3

Changes in functional capacity

Changes in functional capacity will be recorded using the established 6-minute walk test

Time frame
Baseline, after 6 months, after 12 months
4

LDL-Cholesterol

Low density lipoprotein (LDL) is measured in mg/dl

Time frame
Baseline, after 6 months, after 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Essen

Lead sponsor

Universität Duisburg-Essen

Collaborator